Internal Medicine, Medical Oncology · Philadelphia, PA
NPI
1437343597
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
333 Cottman Ave
Philadelphia, PA, 19111
Phone (215) 728-6900
Groups this clinician bills Medicare through
Medicare paid, 2024
$60K
663 services
Medicare patients, 2024
235
Average age 76
Drug cost, 2024
$8.3M
1,892 prescriptions
Company payments, 2025
$18K
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel M Geynisman was code 99215 (office e&m - established), 254 times for 117 patients. In total Daniel M Geynisman billed 663 services in 7 codes, and Medicare paid $60K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-04-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 254 | 117 | $104.85 | $27K |
| 99214 Office E&M - Established | Facility | 238 | 127 | $70.95 | $17K |
| 99214 Office E&M - Established | Office | 98 | 61 | $101.22 | $9,920 |
| 99213 Office E&M - Established | Office | 18 | 16 | $68.87 | $1,240 |
| 99204 Office E&M - New | Facility | 16 | 16 | $94.71 | $1,515 |
| 99205 Office E&M - New | Facility | 16 | 16 | $147.34 | $2,357 |
| 99213 Office E&M - Established | Facility | 14 | 14 | $45.78 | $641 |
By year: 2022 $56K for 620 services; 2023 $61K for 688 services; 2024 $60K for 663 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel M Geynisman prescribed most often to Medicare patients was Abiraterone Acetate, with 347 prescriptions and refills. In total Daniel M Geynisman wrote 1,892 Medicare prescriptions that cost $8.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Abiraterone Acetate Generic | 347 | 347 | 49 | $557K |
| Prednisone Generic | 335 | 414 | 69 | $1,433 |
| Xtandi Enzalutamide | 184 | 184 | 24 | $2.4M |
| Orgovyx Relugolix | 143 | 143 | 22 | $375K |
| Nubeqa Darolutamide | 107 | 107 | 16 | $1.4M |
| Inlyta Axitinib | 53 | 53 | Under 11 | $853K |
| Cabometyx Cabozantinib S-Malate | 41 | 41 | Under 11 | $1.1M |
| Erleada Apalutamide | 39 | 41 | Under 11 | $449K |
| Amlodipine Besylate Generic | 32 | 42 | Under 11 | $107 |
| Oxycodone Hcl Generic | 32 | 32 | 18 | $339 |
| Tamsulosin Hcl Generic | 31 | 67 | Under 11 | $499 |
| Ondansetron Hcl Generic | 29 | 31 | 17 | $264 |
| Potassium Chloride Generic | 22 | 32 | Under 11 | $287 |
| Bicalutamide Generic | 21 | 21 | Under 11 | $324 |
| Pantoprazole Sodium Generic | 21 | 41 | Under 11 | $303 |
Brand drugs: 665 claims; generic drugs: 1,227 claims; opioid claims: 59.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel M Geynisman $18K ($18K in general payments such as food, travel and fees) from 17 companies. The largest payer was Exelixis Inc. with $14K.
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. EXEL | 8 | $14K |
| Avyxa Pharma, LLC | 5 | $3,426 |
| Pfizer Inc. PFE | 6 | $116 |
| Taiho Oncology, Inc. 4578.T | 3 | $75.38 |
| Daiichi Sankyo Inc. 4568.T | 3 | $68.46 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $65.7 |
| Gilead Sciences, Inc. GILD | 1 | $37.78 |
| Merck Sharp & Dohme LLC MRK | 1 | $27.71 |
| Astellas Pharma US Inc 4503.T | 1 | $23.33 |
| Eisai Inc. 4523.T | 1 | $22.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.